FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1519190964> ?p ?o ?g. }

• W1519190964 abstract "The long acting β2-agonists, salmeterol and formoterol, have been recommended, by some, as first line treatment of stable chronic obstructive pulmonary disease (COPD). We reviewed evidence of efficacy and safety when compared with placebo or anticholinergic agents in patients with poorly reversible COPD. After searching MEDLINE, EMBASE, HealthSTAR, BIOSIS Previews, PASCAL, ToxFile, SciSearch, the Cochrane Library, and PubMed, as well as Web sites, selected journals, reference lists, and contacting drug manufacturers, two reviewers independently screened reports of randomised controlled trials of parallel or crossover design lasting four weeks or longer and including patients with a forced expiratory volume in one second (FEV1) ≤ 75% of predicted, a ratio of FEV1 to forced vital capacity (FVC) ≤ 88% of predicted, and < 15% improvement from baseline FEV1 after a dose of a β2 agonist. We included trials comparing salmeterol or formoterol with placebo or with ipratropium bromide and reporting one of these outcomes: lung function; exercise capacity; quality of life scores; dyspnea; exacerbations; rescue inhaler use; incidence of tachycardia, hypokalemia, or dry mouth. Two reviewers assessed the quality of included reports using the Jadad scale and allocation concealment, and abstracted data. Twelve trials satisfied our inclusion criteria; eight were high quality (Jadad score >2) and four were low quality (≤ 2). The adequacy of allocation concealment was unclear in all of them. We did not perform a meta-analysis due to differences in trial design and how outcomes were reported. Two trials comparing salmeterol with ipratropium did not detect differences; one trial comparing formoterol and ipratropium described greater improvement with formoterol in morning PEFR (15.3 versus 7.1 l/min, p = 0.040). Of twelve trials comparing long acting β2 agonists with placebo, six reported no improvement in exercise capacity, eleven reported improvements in FEV1 lung function (one reported no improvement), six reported less rescue inhaler usage (one reported no difference) and five reported improved dyspnea scores (two reported no improvement). Differences in quality of life were detected in one salmeterol trial ; however, two salmeterol, and one formoterol trial reported no differences. Adverse effects of interest were not reported. In terms of clinical outcomes and safety, we could not find convincing evidence that salmeterol and formoterol have demonstrated advantages to ipratropium, a less expensive drug, for patients with stable COPD and poor reversibility. Compared to placebo, we found evidence of reduced rescue inhaler usage and improved spirometric outcomes without a significant impact on quality of life or exercise capacity." @default.
• W1519190964 created "2016-06-24" @default.
• W1519190964 creator A5006331157 @default.
• W1519190964 creator A5036901075 @default.
• W1519190964 creator A5048252284 @default.
• W1519190964 creator A5067738813 @default.
• W1519190964 creator A5089130062 @default.
• W1519190964 date "2004-08-31" @default.
• W1519190964 modified "2023-10-10" @default.
• W1519190964 title "Long acting β2agonists for stable chronic obstructive pulmonary disease with poor reversibility: a systematic review of randomised controlled trials" @default.
• W1519190964 cites W1480729244 @default.
• W1519190964 cites W1970693912 @default.
• W1519190964 cites W1975709340 @default.
• W1519190964 cites W1986215651 @default.
• W1519190964 cites W1989738601 @default.
• W1519190964 cites W2004008756 @default.
• W1519190964 cites W2006193143 @default.
• W1519190964 cites W2007810665 @default.
• W1519190964 cites W2025564699 @default.
• W1519190964 cites W2035236156 @default.
• W1519190964 cites W2038693293 @default.
• W1519190964 cites W2048571011 @default.
• W1519190964 cites W2058723611 @default.
• W1519190964 cites W2079777289 @default.
• W1519190964 cites W2083436606 @default.
• W1519190964 cites W2084702877 @default.
• W1519190964 cites W2088022718 @default.
• W1519190964 cites W2097125229 @default.
• W1519190964 cites W2101012923 @default.
• W1519190964 cites W2110783271 @default.
• W1519190964 cites W2114754430 @default.
• W1519190964 cites W2116446898 @default.
• W1519190964 cites W2120629366 @default.
• W1519190964 cites W2143127068 @default.
• W1519190964 cites W2147412968 @default.
• W1519190964 cites W2150491173 @default.
• W1519190964 cites W2160431793 @default.
• W1519190964 cites W2161052101 @default.
• W1519190964 cites W2166780351 @default.
• W1519190964 cites W2167682972 @default.
• W1519190964 cites W2329480708 @default.
• W1519190964 cites W2397999435 @default.
• W1519190964 cites W4247588765 @default.
• W1519190964 doi "https://doi.org/10.1186/1471-2466-4-7" @default.
• W1519190964 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/517721" @default.
• W1519190964 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15339337" @default.
• W1519190964 hasPublicationYear "2004" @default.
• W1519190964 type Work @default.
• W1519190964 sameAs 1519190964 @default.
• W1519190964 citedByCount "10" @default.
• W1519190964 countsByYear W15191909642015 @default.
• W1519190964 crossrefType "journal-article" @default.
• W1519190964 hasAuthorship W1519190964A5006331157 @default.
• W1519190964 hasAuthorship W1519190964A5036901075 @default.
• W1519190964 hasAuthorship W1519190964A5048252284 @default.
• W1519190964 hasAuthorship W1519190964A5067738813 @default.
• W1519190964 hasAuthorship W1519190964A5089130062 @default.
• W1519190964 hasBestOaLocation W15191909641 @default.
• W1519190964 hasConcept C126322002 @default.
• W1519190964 hasConcept C136524200 @default.
• W1519190964 hasConcept C142724271 @default.
• W1519190964 hasConcept C168563851 @default.
• W1519190964 hasConcept C177713679 @default.
• W1519190964 hasConcept C1862650 @default.
• W1519190964 hasConcept C204787440 @default.
• W1519190964 hasConcept C27081682 @default.
• W1519190964 hasConcept C2776042228 @default.
• W1519190964 hasConcept C2776136866 @default.
• W1519190964 hasConcept C2776478404 @default.
• W1519190964 hasConcept C2776719499 @default.
• W1519190964 hasConcept C2776780178 @default.
• W1519190964 hasConcept C2779871671 @default.
• W1519190964 hasConcept C2780532441 @default.
• W1519190964 hasConcept C2781018748 @default.
• W1519190964 hasConcept C2909577894 @default.
• W1519190964 hasConcept C71924100 @default.
• W1519190964 hasConceptScore W1519190964C126322002 @default.
• W1519190964 hasConceptScore W1519190964C136524200 @default.
• W1519190964 hasConceptScore W1519190964C142724271 @default.
• W1519190964 hasConceptScore W1519190964C168563851 @default.
• W1519190964 hasConceptScore W1519190964C177713679 @default.
• W1519190964 hasConceptScore W1519190964C1862650 @default.
• W1519190964 hasConceptScore W1519190964C204787440 @default.
• W1519190964 hasConceptScore W1519190964C27081682 @default.
• W1519190964 hasConceptScore W1519190964C2776042228 @default.
• W1519190964 hasConceptScore W1519190964C2776136866 @default.
• W1519190964 hasConceptScore W1519190964C2776478404 @default.
• W1519190964 hasConceptScore W1519190964C2776719499 @default.
• W1519190964 hasConceptScore W1519190964C2776780178 @default.
• W1519190964 hasConceptScore W1519190964C2779871671 @default.
• W1519190964 hasConceptScore W1519190964C2780532441 @default.
• W1519190964 hasConceptScore W1519190964C2781018748 @default.
• W1519190964 hasConceptScore W1519190964C2909577894 @default.
• W1519190964 hasConceptScore W1519190964C71924100 @default.
• W1519190964 hasIssue "1" @default.
• W1519190964 hasLocation W15191909641 @default.
• W1519190964 hasLocation W15191909642 @default.
• W1519190964 hasLocation W15191909643 @default.
• W1519190964 hasLocation W15191909644 @default.
• W1519190964 hasOpenAccess W1519190964 @default.

• next